


PHARMACEUTICAL 2018

KERYX BIOPHARMACEUTICALS INC Rank 265 of 349





PHARMACEUTICAL 2018

KERYX BIOPHARMACEUTICALS INC Rank 265 of 349

The relative strengths and weaknesses of KERYX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KERYX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 118% points. The greatest weakness of KERYX BIOPHARMACEUTICALS INC is the variable Other Net Income, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -409%, being 132% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	141,566
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	45,420
Liabilities, Non-Current	894
Other Assets	9,577
Other Compr. Net Income	0
Other Expenses	24,831
Other Liabilities	126,653
Other Net Income	-61,984
Property and Equipment	4,521
Research and Development	37,679
Revenues	60,641
Selling, General and Administrative Expense	99,622

Output Variable	Value in 1000 USD
Assets	158,872
Liabilities	172,967
Expenses	162,132
Stockholders Equity	-14,095
Net Income	-163,475
Comprehensive Net Income	-163,475
Economic Capital Ratio	-409%